Contact
searchSearch
HMP Global
Login

Outcome Measurements

Outcome Measurements
Systematic process of evaluating the effectiveness, safety, and quality of care provided throughout the cancer treatment journey. Measuring outcomes is essential for continuous improvement, refining treatment protocols, and enhancing patient care.

Original Research
Real-World Outcomes of Next-Generation Sequencing of Progressive Radioactive Iodine Refractory Metastatic Thyroid Cancer and Treatment of These Patients With Redifferentiation Protocol
10/15/2025
Jennifer Wheeley, MS, FNP-C; Nikita Chintapally, MD; Kanchan Kulkarni, MD; Gabriel Yohe, MS; Priya Kundra, MD; Jennifer Rosen, MD; Muhammad M. Shaikh, MD; Meeta Sharma, MD; Jason Wexler, MD; Kenneth D. Burman, MD; Leila Shobab, MD; Irina Veytsman, MD
In this study, targeted redifferentiation with BRAF and MEK inhibition restored radioactive iodine avidity in the majority of patients with refractory differentiated thyroid cancer, highlighting a promising therapeutic approach.
In this study, targeted redifferentiation with BRAF and MEK inhibition restored radioactive iodine avidity in the majority of patients with refractory differentiated thyroid cancer, highlighting a promising therapeutic approach.
In this study, targeted...
10/15/2025
Journal of Clinical Pathways
Conference Coverage
Real-World Evidence in Oncology: Opportunities, Challenges, and Clinical Impact
09/10/2025
Grace Taylor, MS, MA
In this CPC+CBEx session, experts debate how real-world evidence can complement clinical trials, accelerate regulatory approvals, and reshape patient care.
In this CPC+CBEx session, experts debate how real-world evidence can complement clinical trials, accelerate regulatory approvals, and reshape patient care.
In this CPC+CBEx session,...
09/10/2025
Journal of Clinical Pathways
Abstracts
Pharmacist-Driven Outcomes for Patients on Oral Oncology Medications: Clinical Impact of an Integrated Specialty Pharmacy Model
08/25/2025
Kishen Patel, PharmD; Martha Stutsky, PharmD; Y. Caleb Chun, MA; Shreevidya Periyasamy, MS; Chelsey Lindner, PharmD, BCOP
In a retrospective evaluation of 6668 patients receiving oral oncology medications through an academic health system specialty pharmacy (HSSP), pharmacist-led interventions—primarily targeting drug safety and adherence—were associated with...
In a retrospective evaluation of 6668 patients receiving oral oncology medications through an academic health system specialty pharmacy (HSSP), pharmacist-led interventions—primarily targeting drug safety and adherence—were associated with...
In a retrospective evaluation of...
08/25/2025
Journal of Clinical Pathways
Abstracts
Green Light, Red Flags: A New Framework for Evaluating Oncology Accelerated Approvals
08/25/2025
Sang Chau, PharmD, BCOP; Justin R. Tse, PharmD, BCOP; Amy VanGalder, PharmD, BCOP; Terra Wonsettler, PharmD, MBA; Andrew Hertler, MD, FACP
To improve transparency and consistency in evaluating oncology therapies granted US Food and Drug Administration (FDA) Accelerated Approval (AA), Evolent developed the Clinical Benefit Index (CBI)—a framework combining the European Society...
To improve transparency and consistency in evaluating oncology therapies granted US Food and Drug Administration (FDA) Accelerated Approval (AA), Evolent developed the Clinical Benefit Index (CBI)—a framework combining the European Society...
To improve transparency and...
08/25/2025
Journal of Clinical Pathways
Research Reports
Total Medical and Pharmacy Costs for Patients With Metastatic Castration-Sensitive Prostate Cancer Initiating Oral Androgen Receptor Pathway Inhibitors in the United States
04/15/2025
Ibrahim Khilfeh, PharmD; Carmine Rossi, PhD; Jill Korsiak; Lilian Diaz, MSc; Bronwyn Moore, BA; Dominic Pilon, MA; Shawn Du, PhD; Lorie Ellis, PhD
In this study, researchers evaluated the total cost of care and components of health care resource use and costs in androgen receptor path­way inhibitor (ARPI)-naïve Medicare-insured patients with metastatic castra­tion-sensitive prostate...
In this study, researchers evaluated the total cost of care and components of health care resource use and costs in androgen receptor path­way inhibitor (ARPI)-naïve Medicare-insured patients with metastatic castra­tion-sensitive prostate...
In this study, researchers...
04/15/2025
Journal of Clinical Pathways
MAI Mindset
December 2023 Pathways Impact Study Part 3: Importance of “on-Pathway” Status for Treatment Selection
06/03/2024
Lee Blansett, MBA
This entry of our MAI Mindset column summarizes the third part of a study by HMP Market Access Insights, which examined the influence and impact pathways have on oncologists’ treatment decisions.
This entry of our MAI Mindset column summarizes the third part of a study by HMP Market Access Insights, which examined the influence and impact pathways have on oncologists’ treatment decisions.
This entry of our MAI Mindset...
06/03/2024
Journal of Clinical Pathways
Research Reports
PSA Outcomes and Clinical Surveillance Among Patients With Nonmetastatic Castration-Resistant Prostate Cancer Treated With a Next-Generation Androgen Receptor Inhibitor in Urology Practices With or Without In-Office Dispensing
06/03/2024
Sabree Burbage; Dexter Waters, MSPH; Carmine Rossi, PhD; Frederic Kinkead; Erik Muser; Lorie Ellis, PhD; Patrick Lefebvre, MA; Dominic Pilon, MA
This study describes prostate-specific antigen (PSA) outcomes and clinical surveillance patterns among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) receiving next-generation androgen receptor inhibitors (ARIs)...
This study describes prostate-specific antigen (PSA) outcomes and clinical surveillance patterns among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) receiving next-generation androgen receptor inhibitors (ARIs)...
This study describes...
06/03/2024
Journal of Clinical Pathways
Research Reports
Patient-Reported Outcomes in Hematopoietic Stem Cell Transplant Recipients: Design, Implementation, and Pilot Results
02/21/2024
Charlotte M. Coughenour; Anna N.A. Tosteson, PhD; Wenyan Zhao, PhD; Christi Ann Hayes, MD; Tor D. Tosteson, PhD; Kenneth R. Meehan, MD; Aricca D. Van Citters, MS; Kate L. Caldon
In a recent study, Christi Ann Hayes, MD, and colleagues aimed to define patient-reported outcome measures in patients receiving hematopoietic stem cell transplant.
In a recent study, Christi Ann Hayes, MD, and colleagues aimed to define patient-reported outcome measures in patients receiving hematopoietic stem cell transplant.
In a recent study, Christi Ann...
02/21/2024
Journal of Clinical Pathways
Research Reports
Clinical and Economic Impact of Implementing HealthPathways at a Musculoskeletal Radiology Department
12/13/2023
Ramakrishna Kishore, MBBS; Khurram Hashmi, MBBCh; Maria Dyban, LLM; Kausik Mukherjee, MBBS; Kathleen Lyons, MBBCh; Anna Kuczynska, MBBCh; Simon R. Davies, MBBCh, MD
Simon R. Davies, MBBCh, and colleagues investigate the impact of HealthPathways on management and primary care clinicians in a musculoskeletal radiology department.
Simon R. Davies, MBBCh, and colleagues investigate the impact of HealthPathways on management and primary care clinicians in a musculoskeletal radiology department.
Simon R. Davies, MBBCh, and...
12/13/2023
Journal of Clinical Pathways
Trending From ACCC
Key Findings from ACCC’s Digital Tools Survey
09/19/2023
This column describes the findings from the 2022 Association of Community Cancer Centers (ACCC) patient survey to identify challenges and benefits associated with wearable devices and other digital tools.
This column describes the findings from the 2022 Association of Community Cancer Centers (ACCC) patient survey to identify challenges and benefits associated with wearable devices and other digital tools.
This column describes the...
09/19/2023
Journal of Clinical Pathways
JCP Nov-Dec Cover

Current Issue

December 2025
Volume 11
Issue 6
Current Issue
Issue Archive

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use